WATCHMAN 2020 - REIMBURSEMENT GUIDE
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
2020
WATCHMAN
REIMBURSEMENT
©2020 Boston Scientific Corporation or its affiliates. All rights reserved. IC-594801-AB REIMBURSEMENT GUIDEINDICATIONS FOR USE The WATCHMAN Device is indicated to reduce the risk of thromboembolism from the left atrial appendage in patients with non-valvular atrial fibrillation who: • Are at increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc scores and are recommended for anticoagulation therapy; • Are deemed by their physicians to be suitable for warfarin; and • Have an appropriate rationale to seek a non-pharmacologic alternative to warfarin, taking into account the safety and effectiveness of the device compared to warfarin. The WATCHMAN Access System is intended to provide vascular and transseptal access for all WATCHMAN Left Atrial Appendage Closure Devices with Delivery Systems. CONTRAINDICATIONS Do not use the WATCHMAN Device if: • Intracardiac thrombus is visualized by echocardiographic imaging. • An atrial septal defect repair or closure device or a patent foramen ovale repair or closure device is present. • The LAA anatomy will not accommodate a device. See Table 46 in the DFU. • Any of the customary contraindications for other percutaneous catheterization procedures (e.g., patient size too small to accommodate TEE probe or required catheters) or conditions (e.g., active infection, bleeding disorder) are present. • There are contraindications to the use of warfarin, aspirin, or clopidogrel. • The patient has a known hypersensitivity to any portion of the device material or the individual components (see Device Description section) such that the use of the WATCHMAN Device is contraindicated. WARNINGS • Device selection should be based on accurate LAA measurements obtained using fluoro and ultrasound guidance (TEE recommended) in multiple angles (e.g., 0º, 45º, 90º, 135º). • Do not release the WATCHMAN Device from the core wire if the device does not meet all release criteria. • If thrombus is observed on the device, warfarin therapy is recommended until resolution of thrombus is demonstrated by TEE. • The potential for device embolization exists with cardioversion
REIMBURSEMENT
REIMBURSEMENT
FOUND IN THIS SECTION
1 WATCHMAN™ Reimbursement Guide
2 Importance of Documentation and the impact on MS-DRG
Assignment-WATCHMAN™
3 WATCHMAN™ Importance of Appropriate Charging Guide
4 Sample Claim Forms
5 WATCHMAN™ Payer List
6 Supporting Patient Access (Prior Authorization and
Appeals Request) – Associated Forms and Templates
• Supporting Patient Access for the WATCHMAN™
LAAC Implant Procedure and Associated Services
• Supporting Forms and Sample Letter Templates
7 LAAO RegistryTHIRD PARTY SOURCES
Health economic and reimbursement information provided by Boston
Scientific Corporation is gathered from third-party sources and is
subject to change without notice as a result of complex and frequently
changing laws, regulations, rules and policies. This information is
presented for illustrative purposes only and does not constitute
reimbursement or legal advice.
Boston Scientific encourages providers to submit accurate and
appropriate claims for services. It is always the provider’s responsibility
to determine medical necessity, the proper site for delivery of any
services and to submit appropriate codes, charges, and modifiers
for services that are rendered. Boston Scientific recommends that
you consult with your payers, reimbursement specialists and/or legal
counsel regarding coding, coverage and reimbursement matters. It is
always the provider’s responsibility to understand and comply with
national coverage determinations (NCD), local coverage determinations
(LCD) and any other coverage requirements established by relevant
payers which can be updated frequently.
REIMBURSEMENT GUIDECONTACT INFORMATION – AT-A-GLANCE
WATCHMAN WATCHMAN WATCHMAN
REIMBURSEMENT IMPORTANCE OF IMPORTANCE OF
GUIDE DOCUMENTATION & APPROPRIATE
This comprehensive guide provides an overview of the coding, THE IMPACT ON MS- CHARGING GUIDE
DRG ASSIGNMENT
coverage and payment landscape for the WATCHMAN system.
For questions regarding WATCHMAN™ reimbursement,
This guide provides education to hospitals on the importance of
please contact:
appropriate charging practices for high cost implantable devices
Email: WATCHMAN.Reimbursement@bsci.com such as the WATCHMAN LAAC Device.
Voicemail: (877) 786-1050 This guide stresses the importance of documentation in capturing
For questions regarding WATCHMAN™ reimbursement,
Press 2 to leave a message. Messages are monitored M-F, the appropriate acuity level for patients considered WATCHMAN
please contact:
8am — 4pm CT and responses are typically on the same or candidates. It helps provide an overview of the common complications
following business day. and comorbidities that assist with the MS-DRG assignment based on Email: WATCHMAN.Reimbursement@bsci.com
patient medical appropriateness.
Phone (toll free): (877) 786-1050 Voicemail: (877) 786-1050
Press 1 to connect with WATCHMAN Prior Authorization For questions regarding WATCHMAN™ reimbursement, Press 2 to leave a message. Messages are monitored M-F,
or Appeal support. please contact: 8am — 4pm CT and responses are typically on the same or
following business day.
Please go to www.watchmandownloadcenter.com to access Email: WATCHMAN.Reimbursement@bsci.com
a sample prior authorization template. Please go to www.watchmandownloadcenter.com to access
Voicemail: (877) 786-1050
a sample prior authorization template.
Press 2 to leave a message. Messages are monitored M-F,
8am — 4pm CT and responses are typically on the same or
following business day.
Phone (toll free): (877) 786-1050
Press 1 to connect with WATCHMAN Prior Authorization
or Appeal support.
Additional WATCHMAN Reimbursement resources are found
on www.watchmandownloadcenter.com
REIMBURSEMENT GUIDE REIMBURSEMENT GUIDE REIMBURSEMENT GUIDE
Email: Email: Email:
WATCHMAN.Reimbursement@bsci.com WATCHMAN.Reimbursement@bsci.com WATCHMAN.Reimbursement@bsci.com
Voicemail: (877) 786-1050 Voicemail: (877) 786-1050 Voicemail: (877) 786-1050
Press 2 to leave a message. Messages Press 2 to leave a message. Messages Press 2 to leave a message. Messages
are monitored M-F, 8am – 4pm CT and are monitored M-F, 8am – 4pm CT and are monitored M-F, 8am – 4pm CT and
responses are typically on the same or responses are typically on the same or responses are typically on the same or
following business day. following business day. following business day.
Phone (toll free): (877) 786-1050 Phone (toll free): (877) 786-1050 Phone (toll free): (877) 786-1050
Press 1 to connect with WATCHMAN Press 1 to connect with WATCHMAN Press 1 to connect with WATCHMAN
Prior Authorization or Appeal support. Prior Authorization or Appeal support. Prior Authorization or Appeal support.
REIMBURSEMENT GUIDEWATCHMAN WATCHMAN WATCHMAN
SAMPLE CLAIM PAYER LIST SUPPORTING
FORMS This document is intended to provide a list of payers that FORMS AND
EXAMPLE
cover WATCHMAN.
For questions regarding WATCHMAN™ reimbursement,
This section is intended to aid hospitals submitting reimbursement please contact:
LETTERS INDEX
forms for the WATCHMAN procedure.
Email: WATCHMAN.Reimbursement@bsci.com
For questions regarding WATCHMAN™ reimbursement, Voicemail: (877) 786-1050
please contact: Press 2 to leave a message. Messages are monitored M-F,
Email: WATCHMAN.Reimbursement@bsci.com 8am — 4pm CT and responses are typically on the same or
following business day.
Voicemail: (877) 786-1050 • Provider Intake Form
Press 2 to leave a message. Messages are monitored M-F, Phone (toll free): (877) 786-1050
• Prior Authorization and Appeals Request Form
8am — 4pm CT and responses are typically on the same or Press 1 to connect with WATCHMAN Prior Authorization
following business day. or Appeal support. • Sample Letter of Medical Necessity (Prior Authorization)
Phone (toll free): (877) 786-1050 Please go to www.watchmandownloadcenter.com to access • Sample Appeal Letter
Press 1 to connect with WATCHMAN Prior Authorization a sample prior authorization template.
• Approval/Coverage Status & Clinical Evidence Summary
or Appeal support.
Please go to www.watchmandownloadcenter.com to access
a sample prior authorization template.
REIMBURSEMENT GUIDE IC-535204-AB REIMBURSEMENT GUIDE REIMBURSEMENT GUIDE
Email: Email: PRIOR AUTHORIZATION TEAM
WATCHMAN.Reimbursement@bsci.com WATCHMAN.Reimbursement@bsci.com Phone (toll free): (877) 786-1050
Press 1 to connect with WATCHMAN
Voicemail: (877) 786-1050 Voicemail: (877) 786-1050
Prior Authorization or Appeal support.
Press 2 to leave a message. Messages Press 2 to leave a message. Messages
are monitored M-F, 8am – 4pm CT and are monitored M-F, 8am – 4pm CT and Email: PreAuthSupport@bsci.com
responses are typically on the same or responses are typically on the same or
following business day. following business day. FAX: 877-835-2520
Phone (toll free): (877) 786-1050 Phone (toll free): (877) 786-1050 REIMBURSEMENT SUPPORT LINE
Press 1 to connect with WATCHMAN Press 1 to connect with WATCHMAN
Prior Authorization or Appeal support. Email:
Prior Authorization or Appeal support.
WATCHMAN.Reimbursement@bsci.com
Voicemail: (877) 786-1050
Press 2 to leave a message. Messages
are monitored M-F, 8am – 4pm CT and
responses are typically on the same or
following business day.
REIMBURSEMENT GUIDEWATCHMAN
REIMBURSEMENT
GUIDE
This comprehensive guide provides an overview of the coding,
coverage and payment landscape for the WATCHMAN system.
For questions regarding WATCHMAN™ reimbursement,
please contact:
Email: WATCHMAN.Reimbursement@bsci.com
Voicemail: (877) 786-1050
Press 2 to leave a message. Messages are monitored M-F,
8am — 4pm CT and responses are typically on the same or
following business day.
Phone (toll free): (877) 786-1050
Press 1 to connect with WATCHMAN Prior Authorization
or Appeal support.
Please go to www.watchmandownloadcenter.com to access
a sample prior authorization template.
IC-528304-AB REIMBURSEMENT GUIDEINDICATIONS FOR USE The WATCHMAN Device is indicated to reduce the risk of thromboembolism from the left atrial appendage in patients with non-valvular atrial fibrillation who: • Are at increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc scores and are recommended for anticoagulation therapy; • Are deemed by their physicians to be suitable for warfarin; and • Have an appropriate rationale to seek a non-pharmacologic alternative to warfarin, taking into account the safety and effectiveness of the device compared to warfarin. The WATCHMAN Access System is intended to provide vascular and transseptal access for all WATCHMAN Left Atrial Appendage Closure Devices with Delivery Systems. CONTRAINDICATIONS Do not use the WATCHMAN Device if: • Intracardiac thrombus is visualized by echocardiographic imaging. • An atrial septal defect repair or closure device or a patent foramen ovale repair or closure device is present. • The LAA anatomy will not accommodate a device. See Table 46 in the DFU. • Any of the customary contraindications for other percutaneous catheterization procedures (e.g., patient size too small to accommodate TEE probe or required catheters) or conditions (e.g., active infection, bleeding disorder) are present. • There are contraindications to the use of warfarin, aspirin, or clopidogrel. • The patient has a known hypersensitivity to any portion of the device material or the individual components (see Device Description section) such that the use of the WATCHMAN Device is contraindicated. WARNINGS • Device selection should be based on accurate LAA measurements obtained using fluoro and ultrasound guidance (TEE recommended) in multiple angles (e.g., 0º, 45º, 90º, 135º). • Do not release the WATCHMAN Device from the core wire if the device does not meet all release criteria. • If thrombus is observed on the device, warfarin therapy is recommended until resolution of thrombus is demonstrated by TEE. • The potential for device embolization exists with cardioversion
2020 WATCHMAN Left Atrial Appendage Closure Device
(The WATCHMAN Device) Coding Guide – Structural Heart
Reimbursement Overview...................................................................................................2
National Coverage Determination (NCD)...........................................................................3
Physician Reimbursement ...................................................................................................5
Physician Coding............................................................................................................5
Co-Surgeon Billing.........................................................................................................6
Echocardiography ..........................................................................................................6
Physician Coverage........................................................................................................8
Physician Payment.........................................................................................................8
Hospital Reimbursement .....................................................................................................9
Hospital Coding..............................................................................................................9
Hospital Payment .........................................................................................................10
Hospital Coverage........................................................................................................ 11
Payer Communications ......................................................................................................12
Prior Authorization Resources...........................................................................................13
Medicare........................................................................................................................13
Medicare Advantage and Other Private Payers .......................................................13
Appealing Denials...............................................................................................................14
Appeal Letter Samples........................................................................................................15
Coding and Reimbursement Support...............................................................................16
On February 8, 2016 CMS established coverage for WATCHMAN under NCD 20.34 f
or percutaneous Left atrial appendage closure (LAAC) therapy.
Boston Scientific is pleased to announce that CMS has finalized the national coverage
determination (NCD) for percutaneous LAAC therapy which provides coverage for
WATCHMAN when specific conditions are met. The effective date of the NCD is
Feb. 8, 2016.
To access the NCD in its entirety, please visit the CMS website or see page 3 of the Guide.
REIMBURSEMENT GUIDEREIMBURSEMENT OVERVIEW
The table below provides an overview of coding, coverage and payment for the
WATCHMAN Left Atrial Appendage Closure (LAAC) Therapy across sites-of-service
and by payer.
Medicare Private Payer
Coding Coverage
Dependent on Payment Coverage Payment
payer contract
Varies by
Hospital Inpatient
NCD for
Most Payer policy
ICD-10 percutaneous
common for LAAC Dependent
procedure LAAC
mappings procedures- on payer
code therapy
are MS-DRG check with contract
02L73DK* effective on
273 or 274 specific
Feb 8, 2016
payer
Hospital Outpatient
Check
Designated with Payer
CPT code Payer
as “Inpatient NA specific
33340 specific
Only” specific
payer
NCD for
percutaneous Per the Refer to
Physician
Dependent
CPT code LAAC Medicare payer policy
on payer
33340 therapy Physician’s for LAAC
contract
effective on Fee Schedule procedures
Feb 8, 2016
2 | REIMBURSEMENT GUIDENATIONAL COVERAGE DETERMINATION
(NCD 20.34)
On February 8, 2016, CMS issued the final decision memo that supports a national
coverage determination (NCD) for Medicare beneficiaries undergoing Percutaneous
Left Atrial Appendage (LAAC) Closure Therapy. NCD 20.34 outlines specific criteria
for WATCHMAN eligibility.
The criteria focus primarily on eligible patients, formal shared decision making, operator
and infrastructure requirements, and submission of certain data to a national registry
for LAAC procedures. The criteria are highlighted below (bolded for emphasis) and we
encourage providers to read the decision memo in its entirety for additional detail.
Eligible Patients
• Must have a CHADS2 score ≥ 2
• CHA2DS2-VASc score ≥ 3
• Show documented evidence of a formal shared decision
interaction between the patient and an independent, non-
interventional physician using an evidenced-based decision
making tool on oral anticoagulants.
1 CMS references the following decision-making tools: http://guidance.nice.org.uk/CG180/
PatientDecisionAid/pdf/English http://www.acponline.org/patients_families/products/
brochures/afib_booklet.pdf
2 The American College of Cardiology provides tools that may also be useful:
http://www.acc.org/tools-and-practice-support/quality-programs/anticoagulation-
initiative/anticoagulation-shared-decision-making-tool https://www.acponline.org/
practice-resources/patient-education/resources
• Suitable for short-term warfarin, but deemed unable
to take long-term oral anticoagulation.
REIMBURSEMENT GUIDE | 3NATIONAL COVERAGE DETERMINATION (NCD 20.34)
Continued
The WATCHMAN Procedure
• The WATCHMAN Procedure must be performed in a hospital
with an established structural heart disease or electrophysiology
program.
• The procedure must be performed by an interventional
cardiologist or electrophysiologist or cardiovascular surgeon
meeting the following criteria:
1. Trained by the manufacturer
2. ≥ 25 interventional cardiac procedures involving transseptal
punctures through an intact septum
3. Continues to perform ≥ 25 interventional cardiac procedures
involving transseptal punctures through an intact septum,
with at least 12 being LAAC over a two year period
• Patients must be enrolled in a prospective national registry.
CMS has certified the LAAO Registry™ (NCT02699957) as the national registry for
data collection for LAAC procedures. The long-term data collection supports CMS’s
coverage with evidence development (CED) to ensure better visibility of safety and
effectiveness of LAAC procedures. The registry certification announcement is located
at: https://www.cms.gov/Medicare/Coverage/Coverage-with-Evidence-Development/
index.html. Hospitals performing WATCHMAN must contact the National
Cardiovascular Data Registry (NCDR®) at ncdr@acc.org or 1-800-257-4737 to
enroll in the LAAO Registry™.
4 | REIMBURSEMENT GUIDEPHYSICIAN REIMBURSEMENT
Physician Coding
Effective January 1, 2017, physicians will report the WATCHMAN implant procedure
using the CPT Code 33340. For CY2020, the work relative value unit (RVU) for this
code is 14.00 with a total RVU of 22.93. The global period for this code is 0 days
CPT Code1 Description
Percutaneous transcatheter closure of the left atrial appendage
with endocardial implant, including fluoroscopy, transseptal
33340 puncture, catheter placement, left atrial angiography, left atrial
appendage angiography, when performed, and radiological
supervision and interpretation
Based on CMS billing instructions, physician claims will need to
have the following items to support the NCD for percutaneous LAAC
procedures.1 For dates of service on or after February 8th (the NCD
effective date), physician claims will be processed only when billed
with the following codes.
• CPT33340
• Primary ICD-10 diagnosis code (one of the following):
- I48.91 – Unspecified atrial fibrillation
- I48.21 – Permanent atrial fibrillation
- I48.0 – Paroxysmal atrial fibrillation
- I48.11 – Longstanding persistent atrial fibrillation
- I48.19 – Other persistent atrial fibrillation
• Place of service code: 21 (inpatient hospital)
• Secondary diagnosis code Z00.6
• Modifier Q0
• Clinical trial number (NCT02699957} in item 23 of
CMS – 1500 form or electronic equivalent
1 MLN Matters® Number MM9638 for Percutaneous Left Atrial Appendage Closure
(LAAC) released on May 6, 2016. https://www.cms.gov/Outreach-and-Education/
Medicare-Learning-Network-MLN/MLNMattersArticles/downloads/MM9638.pdf.
REIMBURSEMENT GUIDE | 5PHYSICIAN REIMBURSEMENT
Continued
Co-surgeon Billing
CPT Code +
Description
Modifier
Left atrial appendage closure can be billed by two surgeons by
33340-62
appending the -62 modifier to 33340 (eg. 33340-62).
This modifier has a two specialty requirement. For example, an EP
and IC can perform the procedure together and bill for their part of
the implantation. Each surgeon will bill 33340-62 and be paid 62.5%
of Medicare’s allowable.
Thus, the total physician payment from Medicare would be at 125%
of what would normally be paid if one surgeon were performing the
procedure. Each operator will be required to submit a post-operative
note outlining their involvement in the procedure. Period for this
code is 0 days.
Echocardiography
Transesophageal echocardiography (TEE) plays a critical role
in visualization and assisting with appropriate candidacy for
the WATCHMAN Device. Based on our Directions for Use, the
WATCHMAN procedure involves use of TEE imaging as follows:
CPT Code Directions for Use
Baseline TEE: Performed prior to the implant procedure
93312 to determine if the patient is a suitable candidate for the
WATCHMAN Device.
Intraoperative TEE: Performed during the WATCHMAN implant
93355 procedure and provides guided imaging to facilitate device
placement.
Follow up TEE: Performed at 45 days and 12 months after the
WATCHMAN implant to ensure appropriate endothelization/
93312
healing of the left atrial appendage (LAA). Based on physician
assessment, additional follow up TEE may be recommended.
6 | REIMBURSEMENT GUIDEPHYSICIAN REIMBURSEMENT
Continued
The baseline and follow up TEE to support the WATCHMAN
procedure may be reported with the following code as appropriate:
CPT Code Description
Echocardiography, transesophageal, real-time with image
documentation (2D) (with or without M-mode recording);
93312
including probe placement, image acquisition, interpretation
and report.
The code 93355 applies to intraoperative TEE’s done during WATCHMAN
and other structural heart interventional procedures. Code, 93355
includes real-time guidance, image acquisition, documentation and
interpretation during transcatheter intracardiac procedures. The work
value for this code is 4.66 with total RVUs of 6.58 for CY2020.
NOTE: Code 93355 is reported once per intervention and only by an individual who is not performing the
interventional procedure (i.e., WATCHMAN implant). A corrective coding initiative (CCI) edit exists with
the code pairs 33340 and 93355 which indicate that these code pairs should not be reported together.
The complete descriptor for code 93355 is: 93355: Echocardiography, transesophageal (TEE) for
guidance of a transcatheter intracardiac or great vessel(s) structural intervention(s) (e.g.,TAVR,
transcatheter pulmonary valve replacement, mitral valve repair, paravalvular regurgitation repair,
left atrial appendage occlusion/closure, ventricular septal defect closure) (peri-and intra-procedural),
real-time image acquisition and documentation, guidance with quantitative measurements, probe
manipulation, interpretation, and report, including diagnostic transesophageal echocardiography
and, when performed, administration of ultrasound contrast, Doppler, color flow, and 3D.
REIMBURSEMENT GUIDE | 7PHYSICIAN REIMBURSEMENT
Continued
Physician Coverage
CMS established a national coverage determination (NCD) for percutaneous LAAC
therapy. The NCD defines specific criteria for physicians and hospitals performing
LAAC therapy with an effective date of February 8, 2016. As a result, codes used to
report the WATCHMAN procedure should no longer be treated as investigational and
experimental technology. Medicare administrative contractors (MACs) and Medicare
Advantage plans must follow the national coverage policy established by the NCD.
We expect WATCHMAN implants performed prior to the NCD effective date would
be adjudicated by the local contractors based on their policies in place at the time of
the WATCHMAN implant.
Private and commercial payers may choose to follow the NCD guidance or establish
their own policies for LAAC therapy. Therefore, it is important to understand payer
policies and seek prior authorizations with private payers to establish the medical
necessity for WATCHMAN in advance of performing the implant.
Resources to support this process are provided in the Payer Communications and Prior
Authorization sections of this document and on the website www.bostonscientific.com.
Physician Payment2
The code used by physicians to report left atrial appendage closure with implant
procedures is 33340. For CY2020, this code has the below values.
National
Code Description RVU
Payment
Percutaneous transcatheter closure
of the left atrial appendage with
implant, including fluoroscopy, 14 work
transseptal puncture, catheter RVU’s
33340 $828
placement(s), left atrial angiography, 22.93 Total
left atrial appendage angiography, RVU’s
radiological supervision and
interpretation.
Commercial payment will vary and will be at discretion of the payer.
Work RVU’s account for the physician’s time, technical skill and effort, mental effort and judgment, and
stress to provide the service
Total RVU’s include work RVU’s as well as practice expense RVUs (nonphysician clinical and nonclinical
labor of the practice, expenses for building space, equipment, and office supplies) and malpractice
RVU’s (accounts for the cost of malpractice insurance premiums).
2 National Average Medicare physician payment rates calculated using the 2020 conversion factor
is 36.0896.
8 | REIMBURSEMENT GUIDEHOSPITAL REIMBURSEMENT
Hospital Coding*
Inpatient hospital procedures will be reported using ICD10 procedure
codes (ICD-10-PCS). The appropriate ICD10 procedure code for
reporting the WATCHMAN implant is 02L73DK:
ICD-10 Procedure Code1 Procedure Description
Occlusion of left atrial appendage with intraluminal
02L73DK
device, percutaneous approach
1 MLN Matters® Number MM9638 for Percutaneous Left Atrial Appendage Closure (LAAC) released
on May 6, 2016. https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/
MLNMattersArticles/downloads/MM9638.pdf
Medicare has determined that the WATCHMAN LAAC procedure must
be performed in the inpatient hospital site of service. The WATCHMAN
procedure is not an approved procedure in the outpatient hospital setting.
The Medicare inpatient-only list of codes is found in Addendum E.
Medicare’s “Inpatient-Only” list at 42 C.F.R. § 419.22(n) defines services
that support an inpatient admission and Part A payment as appropriate,
regardless of the expected length of stay. Therefore, Medicare’s two
midnight rule does not apply to “In-patient Only” procedures. Additional
information can be found by checking this link: https://www.cms.gov/
Research-Statistics-Data-and-Systems/Monitoring-Programs/Medical-
Review/Downloads/ReviewingHospitalClaimsforAdmissionFINAL.pdf
Some private payers may allow the WATCHMAN procedure to be
performed in the hospital outpatient setting, but coverage and payment
will vary so it is important to verify and confirm with your payer.
Based on CMS billing instructions, hospital claims will need to have the
following items to support the NCD for percutaneous LAAC procedures.2
For dates of service on or after February 8th, 2016 (the NCD effective
date), hospital claims will be paid only when billed with the following codes:
• ICD-10 procedure code 02L73DK
• Primary ICD-10 diagnosis code (one of the following):
- I48.91 – Unspecified Atrial Fibrillation
- I48.21 – Permanent Atrial Fibrillation
- I48.0 – Paroxysmal Atrial Fibrillation
REIMBURSEMENT GUIDE | 9HOSPITAL REIMBURSEMENT
Continued
- I48.11 – Longstanding Persistent Atrial Fibrillation
- I48.19 – Other Persistent Atrial Fibrillation
• Secondary diagnosis code Z00.6
• Condition code 30 (Qualifying clinical trial)
• Value code D4: Clinical trial number (NCT02699957)
C-codes*
The WATCHMAN procedure is designated by Medicare as an inpatient
only procedure. Therefore, no C-code is assigned to the WATCHMAN
Device. C-codes are reported for device-intensive procedures performed
in the outpatient hospital site of service.
Hospital Payment
Inpatient services are assigned to Medicare Severity Diagnosis Related Groups
(MS-DRGs) for payment. Based on the inpatient ICD-10-PCS code (02L73DK) and the
most typical diagnosis of atrial fibrillation, WATCHMAN procedures will likely map to
MS-DRG 273 or 274. This assignment is representative of percutaneous intracardiac
procedures such as WATCHMAN LAAC implants, cardiac surgical ablations, and
transcatheter mitral valve replacement procedures.
FY2020
National
MS-DRG MS-DRG Description
Average Base
Payment*
Percutaneous Intracardiac Procedures with
MS-DRG 273 $23,240
MCC
Percutaneous Intracardiac Procedures
MS-DRG 274 $19,792
without MCC
*Centers for Medicare and Medicaid Services. Medicare Program: FY2020 Hospital Inpatient
Prospective Payment System, Final Rule; August 2, 2019.
10 | REIMBURSEMENT GUIDEHOSPITAL REIMBURSEMENT
Continued
Hospital Coverage
As of effective date February 8, 2016, CMS established coverage for the WATCHMAN
LAAC procedure under the NCD for percutaneous LAAC therapy when seven
conditions are met. Upon implementation of CMS’s program instructions, the NCD
creates uniform and consistent coverage for appropriate Medicare beneficiaries...
Medicare Advantage Plans must also follow the NCD. (Please refer to the NCD
coverage section on page 3.) WATCHMAN implants performed prior to the NCD
effective date will be adjudicated by the local contractors based on their policies
in place at the time of the procedure.
CMS is covering LAAC under coverage with evidence development (CED) which
requires data collection to better monitor the long-term efficacy of this therapy on
Medicare beneficiaries. As part of CED, hospitals must participate in the national
registry for LAAC. CMS has certified the National Cardiovascular Data Registry
(NCDR®) LAAO Registry™ (Left Atrial Appendage Occlusion) as the official registry
for the LAAC NCD. Please contact NCDR about enrollment and questions on data
collection by going to the NCDR website, contacting them at ncdr@acc.org or by
calling 1-800-257-4737.
Private and commercial payers may choose to follow the NCD guidance or establish
their own policies for LAAC therapy. Therefore, it is important to seek prior authorizations
with private payers to establish the medical necessity for WATCHMAN in advance of
performing the implant. Resources to support this process are provided in the Payer
Communications and Prior Authorization sections of this document or click on the
website: www.bostonscientific.com.
REIMBURSEMENT GUIDE | 11PAYER COMMUNICATIONS
FDA Approval
The WATCHMAN LAAC Device has received FDA approval so it should not be treated
as an investigational device. Please go to www.bostonscientific.com to access the
FDA approval letter to include in your prior authorization and appeals requests.
The WATCHMAN Device is indicated to reduce the risk of
thromboembolism from the left atrial appendage in patients with
non-valvular atrial fibrillation who:
• Are at increased risk for stroke and systemic embolism based
on CHADS2 or CHA2DS2- VASc3 scores and are recommended
for anticoagulation therapy;
• Are deemed by their physicians to be suitable for warfarin; and
• Have an appropriate rationale to seek a non-pharmacologic
alternative to warfarin, taking into account the safety and
effectiveness of the device compared to warfarin.
Category III CPT Code for the WATCHMAN LAAC Procedure
Effective February 8, 2016, WATCHMAN procedures should no longer
be treated as investigational and experimental by MACs and Medicare
Advantage Plans if patients satisfy all conditions for coverage as defined
in the NCD. It is important to work with MACs and commercial payers
prior to the effective date of the NCD to establish medical necessity
for the procedure via the appeals or prior authorization process.
Private payer, coverage will be based on their policies for LAAC procedures. It is important
that physicians and hospital providers check existing policies in advance of performing
WATCHMAN implants. In addition, physician and hospital providers should always seek
prior authorization for individual coverage consideration of WATCHMAN based on the
patients’ clinical condition. Prior authorization and peer-to-peer reviews are recommended
tools for assisting with patient access in light of private payer non-coverage policies that
may exist in lieu of the NCD. Please refer to the Prior-Authorization section to assist with
best practices in securing approval for WATCHMAN LAAC procedures.
3 January, CT. et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the
Management of Patients With Atrial Fibrillation. JACC. 2019; doi: 10.1161/CIR.0000000000000665.
12 | REIMBURSEMENT GUIDEPRIOR AUTHORIZATION RESOURCES
Traditional Medicare
Medicare fee-for-service does not offer prior authorizations for any
services including the WATCHMAN LAAC procedure.
Medicare Advantage and Other Private Payers
Prior authorization is a process established by commercial insurance plans that
allows a physician to submit a treatment plan prior to surgery. The insurer reviews
the treatment plan as well as the patient’s insurance benefits and medical policies
to determine if the treatment is covered and the applicable patient responsibility
(e.g., coinsurance and/or copay, deductibles, and out-of-pocket amounts). As prior
authorization processes vary by insurer, it is important to contact insurance plans
and follow their specific requirements.
Prior authorization requests typically include the following elements:
• Patient information — name, date of birth, policy number
• Details of the patient’s medical history
• Description of the patient’s current condition and treatment plan
• Letter of medical necessity (LOMN) documenting the patient’s
medical need
• Proposed procedure(s), medical device implanted and rationale
for treatment
• Proposed location of service and dates planned
• Summary of the clinical evidence supporting the treatment
plan including comorbidities and copies of published literature
supporting the safety and effectiveness. Please see References
and Resources page at the end of the Reimbursement Guide for
examples of Peer Review Literature regarding WATCHMAN.
• Description of the technology and rationale for its use
• Copy of the FDA approval letter (available through your
Boston Scientific Sales Representative)
Contact information on At-A-Glance page
REIMBURSEMENT GUIDE | 13APPEALING DENIALS
MACs, commercial and private payers have documented appeals processes for
reconsidering denials. Since Medicare does not perform prior authorizations,
providers would proceed with performing the procedure (based on the patient
meeting the coverage indications as outlined in the NCD), submit the claim to the
MAC, and then wait to receive a payment or denial. If the MAC denies the claim,
Medicare has a defined appeals process with up to five levels of appeals. Additional
information and an overview of this process are found by clicking here. The first level
of Medicare appeal is known as “Redetermination” allows providers to appeal the
denial within 120 days from the date of the initial claim denial. Medicare provides a
specific form (Form CMS-20027) to standardize the information needed to request
initial redeterminations. If you should receive a denial from the Medicare contractor,
you have the right to appeal the claim by referencing the NCD and indicating how
your patient meets the coverage criteria.
In lieu of the NCD for LAAC therapy, many private payers have decided to cover
WATCHMAN, but some plans may continue with existing non-coverage policies.
Therefore, we encourage providers to continue to seek prior authorizations with
private payers to establish medical necessity in advance of performing the procedure.
Should you receive denials, appeals information for the private payers is often found
in the plan’s provider manual and/or website or by contacting the insurer directly. If
you need to appeal a prior authorization denial, physician providers should request
a peer-to-peer review with a like specialty (i.e. Electrophysiology or Interventional
Cardiology) to best communicate the WATCHMAN LAA closure procedure and
patient treatment pathway.
During the peer to peer review, focus on the benefits of the WATCHMAN™ LAAC
technology and the medical necessity based upon the individual patient’s symptoms,
diagnosis and comorbidities. Clinicians may also request a third party peer-to-peer
review of the claim requesting a board-certified Electrophysiologist or cardiologist
who understands the therapy.
Appeal Letters
Appeal letters typically include the following elements for both
Medicare and private payers:
Provide the rationale for filing an appeal (denial of coverage, medical
necessity, etc.)
• Date of denial/denial letter
• Reference the denial reason and associated denial code, if
applicable
14 | REIMBURSEMENT GUIDEAPPEALING DENIALS
Continued
• Detail the patient’s diagnosis and course of treatment including
adverse outcomes or lack of improvement from prior therapies.
• Describe the procedure in detail
• Describe any medical device and its benefits as they relate to
the patient’s condition. Emphasize the advantages of the medical
device as compared to another medical device or approach
• State the rationale and benefits of the technology and how its
use can be expected to produce a superior clinical outcome for
the patient
• Discuss personal experiences and outcomes of surgical cases
using the medical device
• Reference peer review literature to support the clinical
determination regarding medical necessity. Please see References
and Resources page at the end of the Reimbursement Guide for
examples of Peer Review Literature regarding WATCHMAN.
• Provide a contact name and phone number as well as
the willingness to answer questions or provide additional
information
• Request a specific timeframe for a response
Access customizable SAMPLE APPEALS
TEMPLATES at watchmandownloadcenter.com
REIMBURSEMENT GUIDE | 15CODING AND REIMBURSEMENT SUPPORT
Boston Scientific is dedicated to providing physicians, allied health professionals
and hospitals with world-class programs and services to help advance the standard
of patient care and appropriate access to life-enhancing technologies.
REFERENCES AND RESOURCES
Summary of Clinical Evidence
-R
eddy VY, Sievert H, Halperin J, et al. Percutaneous Left Atrial Appendage Closure vs Warfarin for
Atrial Fibrillation: A randomized clinical trial. JAMA. 2014; 312(19): 1988-1998.
-H
olmes DR, Jr., Doshi SK, Kar S, et al. Left Atrial Appendage Closure as an Alternative to Warfarin
for Stroke Prevention in Atrial Fibrillation: A Patient- Level Meta-Analysis. J Am Coll Cardiol. 2015;
65(24):2614-2623.
-R
eddy, V. Y., D. N. Gibson, et al. (2017). “Post-Approval U.S. Experience With Left Atrial Appendage
Closure for Stroke Prevention in Atrial Fibrillation.” Journal of the American College of Cardiology
69(3): 253-261.
-R
eddy, V. Y., S. K. Doshi, et al. (2017). “5-Year Outcomes After Left Atrial Appendage Closure.”
From the PREVAIL and PROTECT AF Trials 70(24): 2964-2975.
- Price, M. J., V. Y. Reddy, et al. (2015). “Bleeding Outcomes After Left Atrial Appendage Closure Compared
With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial
Experience.” JACC: Cardiovascular Interventions 8(15): 1925-1932.
-A
lli, O., S. Doshi, et al. (2013). “Quality of Life Assessment in the Randomized PROTECT AF
(Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of
Stroke in Patients With Atrial Fibrillation) Trial of Patients at Risk for Stroke With Nonvalvular Atrial
Fibrillation.” Journal of the American College of Cardiology 61(17): 1790-1798.
-G
angireddy, S. R., J. L. Halperin, et al. (2012). “Percutaneous left atrial appendage closure for stroke
prevention in patients with atrial fibrillation: an assessment of net clinical benefit.” European Heart
Journal 33(21): 2700-2708.
-H
olmes, DR, Reddy VY, Doshi, SK et al. Percutaneous closure of the left atrial appendage versus
warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomized non-
inferiority trial (PROTECT AF). Lancet. 2009; 374:534-42.
-R
eddy, VY, Doshi, SK, Sievert, H et al. Percutaneous left atrial appendage closure for stroke
prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (WATCHMAN left
atrial appendage system for embolic protection in patients with atrial fibrillation) Trial. Circulation.
2013; 127: 720-729.
16 | REIMBURSEMENT GUIDEREFERENCES AND RESOURCES
Continued
-H
olmes DR, Kar S, Price M, Whisenant B, Sievert H, Doshi S, Huber K, Reddy V.Prospective randomized
evaluation of the WATCHMAN left atrial appendage Device in patients with atrial fibrillation versus
long-term warfarin therapy; the PREVAIL trial. Journal of the American College of Cardiology, Vol. 4,
No. 1, 2014, 1-11.
-R
eddy VY, Sievert H, Halperin J, et al. Percutaneous Left Atrial Appendage Closure vs Warfarin for
Atrial Fibrillation: A randomized clinical trial. JAMA. 2014; 312(19): 1988-1998.
-H
olmes DR, Jr., Doshi SK, Kar S, et al. Left Atrial Appendage Closure as an Alternative to Warfarin for
Stroke Prevention in Atrial Fibrillation: A Patient- Level Meta-Analysis. J Am Coll Cardiol. 2015; 65(24):
2614-2623.
-R
eddy, V. Y., D. N. Gibson, et al. (2017). “Post-Approval U.S. Experience With Left Atrial Appendage
Closure for Stroke Prevention in Atrial Fibrillation.” Journal of the American College of Cardiology
69(3): 253-261.
-R
eddy, V. Y., S. K. Doshi, et al. (2017). “5-Year Outcomes After Left Atrial Appendage Closure.”
From the PREVAIL and PROTECT AF Trials 70(24): 2964-2975.
- Price, M. J., V. Y. Reddy, et al. (2015). “Bleeding Outcomes After Left Atrial Appendage Closure
Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN
Randomized Trial Experience.” JACC: Cardiovascular Interventions 8(15): 1925-1932.
-A
lli, O., S. Doshi, et al. (2013). “Quality of Life Assessment in the Randomized PROTECT AF
(Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of
Stroke in Patients With Atrial Fibrillation) Trial of Patients at Risk for Stroke With Nonvalvular
Atrial Fibrillation.” Journal of the American College of Cardiology 61(17): 1790-1798.
-G
angireddy, S. R., J. L. Halperin, et al. (2012). “Percutaneous left atrial appendage
closure for stroke prevention in patients with atrial fibrillation: an assessment of
net clinical benefit.” European Heart Journal 33(21): 2700-2708.
Reimbursement Guide References
1 CPT copyright 2016 American Medical Association. All rights reserved. CPT is a registered trademark
of the American Medical Association. Applicable FARS/DFARS Restrictions Apply to Government Use.
Fee schedules, relative value units, conversion factors, and/or related components are not assigned by
the AMA, are not part of CPT®, and the AMA is not recommending their use.
The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA
assumes no liability for data contained or not contained herein.
2 American Medical Association: 2017 ICD-10-PCS for Hospitals—The Complete Official Draft Code Set,
Professional Edition, Chicago, IL.
REIMBURSEMENT GUIDE | 17WATCHMAN
IMPORTANCE OF
DOCUMENTATION &
THE IMPACT ON MS-
DRG ASSIGNMENT
This guide stresses the importance of documentation in capturing
the appropriate acuity level for patients considered WATCHMAN
candidates. It helps provide an overview of the common complications
and comorbidities that assist with the MS-DRG assignment based on
patient medical appropriateness.
For questions regarding WATCHMAN™ reimbursement,
please contact:
Email: WATCHMAN.Reimbursement@bsci.com
Voicemail: (877) 786-1050
Press 2 to leave a message. Messages are monitored M-F,
8am — 4pm CT and responses are typically on the same or
following business day.
Phone (toll free): (877) 786-1050
Press 1 to connect with WATCHMAN Prior Authorization
or Appeal support.
Additional WATCHMAN Reimbursement resources are found
on www.watchmandownloadcenter.com
IC-528021-AB REIMBURSEMENT GUIDEINDICATIONS FOR USE The WATCHMAN Device is indicated to reduce the risk of thromboembolism from the left atrial appendage in patients with non-valvular atrial fibrillation who: • Are at increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc scores and are recommended for anticoagulation therapy; • Are deemed by their physicians to be suitable for warfarin; and • Have an appropriate rationale to seek a non-pharmacologic alternative to warfarin, taking into account the safety and effectiveness of the device compared to warfarin. The WATCHMAN Access System is intended to provide vascular and transseptal access for all WATCHMAN Left Atrial Appendage Closure Devices with Delivery Systems. CONTRAINDICATIONS Do not use the WATCHMAN Device if: • Intracardiac thrombus is visualized by echocardiographic imaging. • An atrial septal defect repair or closure device or a patent foramen ovale repair or closure device is present. • The LAA anatomy will not accommodate a device. See Table 46 in the DFU. • Any of the customary contraindications for other percutaneous catheterization procedures (e.g., patient size too small to accommodate TEE probe or required catheters) or conditions (e.g., active infection, bleeding disorder) are present. • There are contraindications to the use of warfarin, aspirin, or clopidogrel. • The patient has a known hypersensitivity to any portion of the device material or the individual components (see Device Description section) such that the use of the WATCHMAN Device is contraindicated. WARNINGS • Device selection should be based on accurate LAA measurements obtained using fluoro and ultrasound guidance (TEE recommended) in multiple angles (e.g., 0º, 45º, 90º, 135º). • Do not release the WATCHMAN Device from the core wire if the device does not meet all release criteria. • If thrombus is observed on the device, warfarin therapy is recommended until resolution of thrombus is demonstrated by TEE. • The potential for device embolization exists with cardioversion
THE IMPORTANCE OF MEDICAL
DOCUMENTATION
Often times, physicians hear the mantra, “If it isn’t documented in the medical record,
then it didn’t happen.” This is important from a compliance and reporting perspective
because appropriately capturing a patient’s clinical condition impacts how hospitals
are reimbursed under the Medicare severity-adjusted DRG system. Under this system,
payment is influenced by the patient’s age, gender and diagnosis codes. Specificity of
both the principal and secondary diagnoses is imperative to reimbursement accuracy.
The accurate presentation of patient risks and illness severity helps hospitals receive
appropriate reimbursement for the care of these patients.
Major Complications and Comorbidities
The presence of a major complication or comorbidity (MCC) or complication or
comorbidity (CC) generally is representative of a patient that requires more resources;
therefore, hospitals are paid more to care for these patients. Greater specificity in
documenting the patient’s diagnosis allows the coder to select the diagnosis code
which most accurately reflects the patient’s condition resulting in assignment to the
appropriate MS-DRG.
The WATCHMAN Left Atrial Appendage (LAA) closure procedures map most
commonly to MS-DRGs 273 and 274 when reported with inpatient procedure
code: 02L73DK (Insertion of a left atrial appendage device, transseptal catheter
technique) and the common diagnosis of atrial fibrillation. Below are the
aforementioned MS-DRG descriptors:
DRGs Description
MS-DRG
Percutaneous Intracardiac Procedures with MCC
273
MS-DRG
Percutaneous Intracardiac Procedures without MCC
274
Medicare Program: FY2020 Hospital Inpatient Prospective Payment System, Final Rule; Updated
August 2, 2018. Payment based on FY2020 National Base Payment).
REIMBURSEMENT GUIDETHE IMPORTANCE OF MEDICAL DOCUMENTATION
Continued
MS-DRG 273
YES YES $23,240
WATCHMAN
LAA LAA Closure Major Complications
Closure procedure or Comorbidities?
Procedure
Code: 02L73DK NO MS-DRG 274
$19,792
Example
The examples below represent different levels of acuity for a patient that presents with
atrial fibrillation and undergoes the WATCHMAN LAA Closure procedure (inpatient
code: 02L73DK). The examples demonstrate how the presence of a major complication
or comorbidity (MCC) impacts the MS-DRG assignment.
Example #1
Codes Description
I48.91
I48.21
I48.0 Principal diagnosis: Atrial Fibrillation
I48.11
I48.19
Encounter for examination for normal comparison and control
Z00.6
in clinical research program
MS-DRG MS-DRG assignment: Percutaneous Intracardiac Procedures
274 without MCC
FY2020 National Base Payment: $19,793
REIMBURSEMENT GUIDETHE IMPORTANCE OF MEDICAL DOCUMENTATION
Continued
Example #2
Codes Description
I48.91
I48.21
I48.0 Principal diagnosis: Atrial Fibrillation
I48.11
I48.19
Encounter for examination for normal comparison and control
Z00.6
in clinical research program
Secondary diagnosis: Acute on chronic diastolic heart failure.
I50.33 Diagnosis code I50.33 is classified as a major complication and
comorbidity.
MS-DRG MS-DRG assignment: Percutaneous Intracardiac Procedures
273 with MCC
FY2020 National Base Payment: $23,240
Medicare Program: FY2020 Hospital Inpatient Prospective Payment System, Final Rule; Updated
August 2, 2018. Payment based on FY 2020 National Base Payment).
Below is an example of some of the MCC, CC, and non-CC conditions that may be
relevant to your WATCHMAN™ Implant patients. This is not an all-inclusive list and
providers should refer to the CMS website (Tables 6I and 6J) for a comprehensive and
current year’s listing of those diagnosis codes that are considered MCC’s and CC’s.
Please note that any diagnosis code not on the MCC or CC list is considered a non CC
diagnosis code and represents the lowest level of severity of illness and resource use.
REIMBURSEMENT GUIDETHE IMPORTANCE OF MEDICAL DOCUMENTATION
Continued
Major Complications/Comorbid Conditions (Top 9 Reported)
Codes Description
N18.6 End stage renal disease
I50.33 Acute on chronic diastolic (congestive) heart failure
150.23 Acute on chronic systolic (congestive) heart failure
J96.01 Acute respiratory failure with hypoxia
J95.821 Acute post-procedural respiratory failure
Acute respiratory failure, unspecified whether with hypoxia
J96.00
or hypercapnia
I50.31 Acute diastolic (congestive) heart failure
J18.9 Pneumonia, unspecified organism
Acute on chronic combined systolic (congestive) and diastolic
I50.43
(congestive) heart failure
Since physicians were limited by the inclusion and exclusion criteria of the WATCHMAN
clinical trials (PROTECT AF, CAP, PREVAIL, CAP II), most WATCHMAN Implant patients
in the trials mapped to MS-DRG 251. The current MS-DRGs for WATCHMAN are 273
and 274. Thus, it is important that physicians appropriately assess their WATCHMAN
Implant eligible patients to ensure that documentation supports the appropriate level
of patient acuity.
NOTE: Please note that coding is complicated and it is important that healthcare providers work with
their coders to achieve complete and accurate documentation, code assignment, and reporting of
diagnoses and procedures. Complete documentation in the medical record cannot be overemphasized.
REIMBURSEMENT GUIDEWATCHMAN
IMPORTANCE OF
APPROPRIATE
CHARGING GUIDE
This guide provides education to hospitals on the importance of
appropriate charging practices for high cost implantable devices
such as the WATCHMAN LAAC Device.
For questions regarding WATCHMAN™ reimbursement,
please contact:
Email: WATCHMAN.Reimbursement@bsci.com
Voicemail: (877) 786-1050
Press 2 to leave a message. Messages are monitored M-F,
8am — 4pm CT and responses are typically on the same or
following business day.
Please go to www.watchmandownloadcenter.com to access
a sample prior authorization template.
IC-528305-AB REIMBURSEMENT GUIDEINDICATIONS FOR USE The WATCHMAN Device is indicated to reduce the risk of thromboembolism from the left atrial appendage in patients with non-valvular atrial fibrillation who: • Are at increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc scores and are recommended for anticoagulation therapy; • Are deemed by their physicians to be suitable for warfarin; and • Have an appropriate rationale to seek a non-pharmacologic alternative to warfarin, taking into account the safety and effectiveness of the device compared to warfarin. The WATCHMAN Access System is intended to provide vascular and transseptal access for all WATCHMAN Left Atrial Appendage Closure Devices with Delivery Systems. CONTRAINDICATIONS Do not use the WATCHMAN Device if: • Intracardiac thrombus is visualized by echocardiographic imaging. • An atrial septal defect repair or closure device or a patent foramen ovale repair or closure device is present. • The LAA anatomy will not accommodate a device. See Table 46 in the DFU. • Any of the customary contraindications for other percutaneous catheterization procedures (e.g., patient size too small to accommodate TEE probe or required catheters) or conditions (e.g., active infection, bleeding disorder) are present. • There are contraindications to the use of warfarin, aspirin, or clopidogrel. • The patient has a known hypersensitivity to any portion of the device material or the individual components (see Device Description section) such that the use of the WATCHMAN Device is contraindicated. WARNINGS • Device selection should be based on accurate LAA measurements obtained using fluoro and ultrasound guidance (TEE recommended) in multiple angles (e.g., 0º, 45º, 90º, 135º). • Do not release the WATCHMAN Device from the core wire if the device does not meet all release criteria. • If thrombus is observed on the device, warfarin therapy is recommended until resolution of thrombus is demonstrated by TEE. • The potential for device embolization exists with cardioversion
You can also read
